Reduction in vascular endothelial growth factor expression in the superior temporal, hippocampal, and brainstem regions in alzheimer's disease

Current Neurovascular Research

Volumn 11, Issue 3, 2014, Pages 202-209

  Provias, John ^a   Jeynes, Brian ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b BROCK UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Blood brain barrier; Senile plaques; VEGF

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; VASCULOTROPIN;

ADULT; AGED; ALZHEIMER DISEASE; ANGIOGENESIS; ARTICLE; AUTOPSY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MIDDLE AGED; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENILE PLAQUE; TEMPORAL CORTEX; AMYLOID PLAQUE; BRAIN CAPILLARY ENDOTHELIAL CELL; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; SUPERIOR TEMPORAL CORTEX; VERY ELDERLY;

EID: 84906860108     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202611666140520122316     Document Type: Article

References (40)

1. Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 2011; Jun 10; e19. doi:1017/S1462399411001918
2. Armato U, Chakravarthy B, Pacchiana R, Whitfield JF. Alzheimer's disease: An update of the roles of receptors, astrocytes and primary cilia (review). Int J Mol Med 2013; 31(1): 3-10
3. Jeynes B, Provias J. The Case for Blood-Brain Barrier Dysfunction in the Pathogenesis of Alzheimer's Disease. J Neurosci Res 2011; 89 (1): 22-28
4. Jeynes B, Provias J. Evidence for Altered LRP/RAGE Expression in Alzheimer Lesion Pathogenesis. Curr Alz Res 2008; 5(5): 432-437
5. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier A beta clearance in Alzheimer's disease. Curr Pharm Des 2008; 14(16): 1601-1605
6. Zlokovic BV. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherpeutics 2008; 5(3): 409-414
7. Jeynes B, Provias J. P-Glycoprotein Altered Expression in Alzheimer's disease: Regional Anatomic Variability. Available from: Hindawi Publishing Corporation, Journal of Neurodegenerative Diseases, Volume 2013, Article ID 257953, http://dx.doi.org/10.1155/2013/257953
8. Provias J, Jeynes B. 2011. Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. Curr Alz Res 2011; 8(2): 197-202
9. Religa P, Cao R, Religa D, et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci Rep 2013; 3: 2053. doi: 10.1038/srep02053
10. Huang L, Jia J, Liu R. Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer's disease and amnestic mild cognitive impairment. Neurosci Lett 2013; 550(6): 60-63
11. Yang, SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB. Coaccumulation of vascular endothelial growth factor with betaamyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 2004; 25(3): 283-290
12. Sanchez A, Tripathy D, Luo J, Yin X, Martinez J, Grammas P. Neurovascular unit and the effects of dosage in VEGF toxicity: Role for oxidative stress and thrombin. J Alz Dis 2013; 34(1): 281-291
13. He D, Lu W, Chang K, Liu Y, Zhang J, Zeng Z. Vascular endothelial growth factor polymorphisms and risk of Alzheimer's disease: A meta-Analysis. Gene 2013; 518(2): 296-302
14. Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaMann, JC, Lust WD. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 1998; 62(1): 101-5
15. Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010; 30(4): 1417-1425
16. Tang H, Mao X, Xie L, Greenberg DA, Jin K. Expression level of vascular endothelial growth factor in hippocampus is associated with cognitive impairment in patients with Alzheimer's disease. Neurobiol Aging 2013; 34(5): 1412-1415
17. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica (Berl) 1991; 82(4): 239-259
18. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41(4): 479-486
19. Yang S-P, Kwon BO, Gho YS, Chae C-B. Specific interaction of VEGF165 with β-Amyloid, and its protective effect on β-Amyloidinduced neurotoxicity. J Neurochem 2005; 93(1): 118-127
20. Rocchi A, Orsucci D, Tognoni G, Ceravolo R, Siciliano G. The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. Curr Alz Res 2009; 6(3): 224-37.
21. Tarkowski E, Issa R, Sjögren,M, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002; 23(2): 237-243
22. Luo J, Martinez J, Yin X, Sanchez A, Tripathy D, Grammas P. Hypoxia induces angiogenic factors in brain microvascular endothelial cells. Microvasc Res 2012; 83(2): 138-145
23. Mateo I, Llorca J, Infante J, et al. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand 2007; 116(1): 56-58
24. Hu WT, Chen-Plotkin A, Arnold SE, et al. Novel CSF biomarkers for Alzheimer's Disease and mild cognitive impairment. Acta Neuropathol 2010; 119(6): 669-78
25. Garcia KO, Ornellas FL, Martin PK, Patti CL, Mello LE, Frussa- Filho R, et al. Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer's disease. 2014; Front Aging Neurosci 6:30. doi: 10.3389/fnagi.2014.00030
26. Huang L, Jia J, Liu R. Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer's disease and amnestic mild cognitive impairment.2013; Neurosci Lett 550:60-3. doi: 10.1016/j.neulet.2013.06.031
27. Miners S, Moulding H, de Silva R, Love S. Reduced Vascular Endothelial Growth Factor and Capillary Density in the Occipital Cortex in Dementia with Lewy Bodies. 2014; Brain Pathol doi: 10.1111/bpa.12130
28. Bürger S, Noack M, Kirazov LP, et al. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-Amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci 2009; 27(6): 517-523
29. Wang P, Xie ZH, Guo YJ, et al. VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. Biochem Biophysical Res Comm 2011; 411(3): 620-626
30. Spuch C, Antequera D, Portero A, et al. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. Biomaterials 2010; 31(21): 5608-5618
31. Antequera D, Portero A, Bolos M, et al. Encapsulated VEGFsecreting cells enhance proliferation on neuronal progenitors in the hippocampus of AβPP/PWS1 mice. J Alz Dis 2012; 29(1):187-200
32. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009; 89(2): 607-648
33. Yuan Q, Zuo X, Jia J. Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among Northern Chinese Han. Neurosci Lett 2009; 457(3): 133-136
34. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci 2009; 283(1-2): 66-68
35. Chapuis J, Tian J, Shi J, et al. Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease. Neurobiol Aging 2006; 27(9): 1212-1215
36. Chiappelli M, Borroni B, Archetti S, et al. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuv Res 2006; 9(4): 485-493
37. Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean? Alzheimer's Dement 2014; pii: S1552-5260(14)00029-6
38. Guo LH, Alexopoulos P, Perneczky R. Heart-type fatty acid binding protein and vascular endothelial growth factor: Cerebrospinal fluid biomarker candidates for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2013; 263(7): 553-60
39. Blasko I, Lederer W, Oberbauer H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 2006; 21(1): 9-15
40. Storkebaum E, Carmeliet P. VEGF: A critical player in neurodegeneration. J Clin Invest 2004; 113(1): 14-18